1. Most Discussed
  2. Gainers & Losers

first half results

  1. asmizon

    762 Posts.

    Gradipore Releases First Half Results
    25 Feb 2003

    Gradipore Limited released today its financial results for the six months ending 31 December 2002. During the period the Company recorded a 26% increase in sales to $2.45 million from $1.95 million recorded in the prior year. A net loss for the six months of $7.9 million compares with $8.1 million for the previous corresponding period.

    In announcing the results today, Gradipore's CEO, Robert Lieb, indicated that while sales growth was strong, the financial performance for the half was below internal budget forecasts.

    "The results are mixed - encouraging in some respects and disappointing in others. In the first half, we achieved a 26% increase in sales over last year, but this lagged our budget targets and resulted in a loss close to last year's levels. Revenue in the second quarter was somewhat lower than anticipated primarily due to timing issues in all three Business Units.”

    “Our key short term commitment remains to drive revenue growth while holding expenditure rates down and so reduce the operating deficit. In the second half, we expect to see strong and continuing sales growth; expenditure levels will fall following the staff reductions announced in January and the sharper focus on key business opportunities," Mr Lieb said.

    Summary of Financial Results for 6 Months Ended 31 December 2002

    6 months to

    6 months to
    6 months to







    R&D Grant


    Operating revenue


    Operating expenses

    Operating loss


    Net interest earned


    Net loss


    * Includes $510,000 in redundancy and retirement expense at Board and senior management levels

    Reviewing Business Unit performance:

    In our Life Science Business Unit, the launch of Gradipore's new and complete range of electrophoresis gels, originally scheduled for the second quarter, was delayed by approximately 8 weeks due to necessary steps to assure product quality. The complete range is now on the market, the products are being well received by customers and sales are now responding. We are confident that second half performance will show sharp improvement. The BF400 Gradiflow separation instrument for research applications moved from the beta testing phase to marketing launch in January 2003. This is an important development and will contribute to revenue growth in the current half.

    The Diagnostics Business Unit had experienced a slow second quarter sales due to delays in receiving several expected large orders. This situation has resolved itself in the current quarter, with record sales achieved in January. As a result, sales in this Business Unit are now tracking ahead of budget.

    The Commercial Separations Business Unit forecasted several agreements to be signed and partially billed in the first half. Delayed signings, often the result of due diligence by both parties, reduced the revenue contribution from this business. This situation will improve in the second half - as reflected in the announced agreements with Cangene, Advantek and now Serologicals.


    The Board considers it unlikely that the Company can achieve its stated goals to halve the operating deficit for the fiscal year. Revenues from the Commercial Separations business unit in particular are lumpy and difficult to forecast. Nonetheless, our current forecast anticipates the second half loss to be significantly lower – in the range of $4 million.

    About Gradipore

    Gradipore (ASX Code: GDP) is an Australian global biotechnology company which researches, develops, manufactures and markets hematological and separation technologies principally to provide increased efficiency for research and development for the life science market throughout the world.

    Gradipore’s core separations technology platform, Gradiflow, is a unique membrane-based process for biological separations and has a wide range of applications in research, scientific and commercial environments including blood purification and biological drug manufacturing. Unlike other blood purification technologies, Gradiflow can purify proteins and remove viral and bacterial pathogens (and now prion proteins) simultaneously.

    For information on Gradipore, visit the company’s corporate web site at www.gradipore.com

    Investor inquiries -
    Media inquiries -

    Simone Lockwood
    David Lumb or Jonathan Revitt

    Gradipore Limited
    Porter Novelli

    (02) 8977-9000
    (02) 9463 7600

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.